Inclusion Criteria:

• Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations.
• Subjects with histologically or cytologically confirmed solid tumor who have failed or refused standard therapies or for which no approved therapy is available.
• Age greater than or equal to 18 years at the time of informed consent.
• ECOG performance status of less than or equal to 2.

• Required laboratory values:

  • ANC greater than or equal to 1500 cells/mm3
  • Platelet count greater than or equal to 100,000 cells/mm3
  • Hemoglobin greater than or equal to 9 gm/L
  • Total bilirubin less than or equal to1.5 x upper limit of normal (ULN)
  • ALT or AST less than or equal to 2.5 x ULN
  • Serum creatinine less than or equal to 2.0 x ULN or calculated creatinine clearance greater than or equal to 60 mL/min/1.73m2
  • INR less than or equal to 1.3
• Plasma cortisol and ACTH
• Male and female subjects of childbearing potential must practice effective double barrier contraception during the study and continue contraception for 3 months after their last dose of study treatment.

Exclusion Criteria:

• Pregnant (positive pregnancy test) or nursing women.
• Prior treatment with Hsp90 inhibitors at any time.
• Prior antitumor therapies, including prior experimental agents or approved antitumor small molecules and biologics within 28 days and all associated toxicities resolved to eligibility levels.
• Prior radiation or surgery should have been completed greater than or equal to 4 weeks prior to study enrollment and all associated toxicities resolved to eligibility levels.
• Subjects with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other AEs.
• Concurrent severe or uncontrolled medical disease (i.e., diabetes, hypertension, coronary artery disease, congestive heart failure), which in the opinion of the Investigator and/or the Sponsor could compromise protocol objectives.
• Subjects with screening or baseline prolongation of QTc interval > 450 msec for males or > 470 msec for females.
• Myocardial infarction within past 12 months from time of enrollment in this study.
• History of arterial or venous thrombosis within past 6 months from time of enrollment in this study.
• Red blood cell (RBC) or platelet transfusion within 30 days of screening.
• Active symptomatic fungal, bacterial, and/or known viral infection, including active HIV or viral (A, B, or C) hepatitis including hepatitis C-seropositivity (unless HCV RNA PCR negative), or hepatitis B surface antigen (HBsAg)-seropositivity
• Problems with swallowing or malabsorption.
• Chronic diarrhea (excess of 2 to 3 stools/day above normal frequency).
• Inflammatory gastrointestinal diseases including gastritis, ulcerative colitis, Crohn's disease, or hemorrhagic coloproctitis.
• History of gastrectomy or major surgery to the small intestine.